First Hawaiian Bank Has $767,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

First Hawaiian Bank increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 13.9% in the first quarter, Holdings Channel.com reports. The firm owned 5,096 shares of the medical research company’s stock after purchasing an additional 620 shares during the quarter. First Hawaiian Bank’s holdings in Charles River Laboratories International were worth $767,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Optiver Holding B.V. acquired a new position in Charles River Laboratories International in the 4th quarter worth $37,000. GeoWealth Management LLC boosted its stake in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the 4th quarter worth $48,000. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares during the period. Finally, Huntington National Bank boosted its stake in Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock worth $55,000 after purchasing an additional 164 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 1.6%

Shares of CRL stock opened at $135.51 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm’s 50-day moving average is $129.03 and its 200-day moving average is $160.44. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of 903.40, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analysts’ expectations of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.27 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Barclays increased their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 8th. Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Robert W. Baird increased their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, May 8th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $171.85.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).